ObesityPhase 3TRIUMPH-3NCT05882045
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
A Phase 3 study testing Retatrutide in people with Obesity and Cardiovascular Diseases, run by Eli Lilly and Company at 169 sites in 10 countries.
Trial summary
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Obesity, Cardiovascular Diseases
- What is being tested?
- Retatrutide
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1,946 participants
- Where
- 169 sitesin 10 countries
- Study dates
- 30 May 2023to 14 May 2026
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Have a body mass index (BMI) ≥35.0 kilogram/square meter (kg/m²).
- Have established cardiovascular (CV) disease with at least 1 of the following:
- prior myocardial infarction
- prior ischemic or hemorrhagic stroke, or
- symptomatic peripheral arterial disease
- Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight.
Who cannot join
- Have had acute myocardial infarction, stroke, coronary revascularization, hospitalization for unstable angina, or hospitalization due to congestive heart failure within 90 days prior to screening.
- Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening.
- Have a prior or planned surgical treatment of obesity.
- Have a change in body weight greater than 5 kg (11 pounds) within 90 days prior to screening.
- Have Type 1 diabetes.
- Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
- Have had pancreatitis.
Trial locations and contacts
169 sites in 10 countries.
169 sites in 10 countries
United States46 sites
Texas Diabetes & Endocrinology, P.A.
Austin, Texas, 78731
Pinnacle Clinical Research
Austin, Texas, 78757
Elite Clinical Trials
Blackfoot, Idaho, 83221
Humphreys Diabetes Center
Boise, Idaho, 83702
Northwestern University
Chicago, Illinois, 60611
StudyMetrix Research
City of Saint Peters, Missouri, 63303
Cleveland Clinic
Cleveland, Ohio, 44195
South Texas Clinical Research
Corpus Christi, Texas, 78404
Valley Clinical Trials, Inc.
Covina, California, 91723
Altoona Center For Clinical Research
Duncansville, Pennsylvania, 16635
Neuro-Pain Medical Center
Fresno, California, 93710
Valley Research
Fresno, California, 93720
Tribe Clinical Research, LLC
Greenville, South Carolina, 29607
Great Lakes Clinical Trials - Gurnee
Gurnee, Illinois, 60031
Indago Research & Health Center, Inc
Hialeah, Florida, 33012
Pacific Diabetes & Endocrine Center
Honolulu, Hawaii, 96817
Brengle Family Medicine
Indianapolis, Indiana, 46260
Clinical Neuroscience Solutions, Inc. dba CNS Healthcare
Jacksonville, Florida, 32256
Las Vegas Medical Research
Las Vegas, Nevada, 89128
Palm Research Center Tenaya
Las Vegas, Nevada, 89128
Collaborative Neuroscience Research, LLC
Los Alamitos, California, 90720
Velocity Clinical Research, Westlake
Los Angeles, California, 90057
Southern Endocrinology Associates
Mesquite, Texas, 75149
Carteret Medical Group
Morehead City, North Carolina, 28557
Trial Management Associates
Myrtle Beach, South Carolina, 29572
Weill Cornell Medical College
New York, New York, 10021
Valley Clinical Trials, Inc.
Northridge, California, 91325
Advanced Research Institute
Ogden, Utah, 84405
Clinical Neuroscience Solutions, Inc.
Orlando, Florida, 32801
Charter Research - Winter Park
Orlando, Florida, 32803
Central Phoenix Medical Clinic
Phoenix, Arizona, 85020
UPMC Montefiore University Hospital
Pittsburgh, Pennsylvania, 15213
Progressive Medical Research
Port Orange, Florida, 32127
Rainier Clinical Research Center
Renton, Washington, 98057
Rochester Clinical Research, LLC
Rochester, New York, 14609
Texas Diabetes & Endocrinology, P.A.
Round Rock, Texas, 78681
Sleep Therapy Research Center
San Antonio, Texas, 78229
Consano Clinical Research, LLC
Shavano Park, Texas, 78231
Tribe Clinical Research - Spartanburg
Spartanburg, South Carolina, 29301
Central Illinois Diabetes and Clinical Research a Division of Prairie Education and Research Cooperative
Springfield, Illinois, 62711
Cotton O'Neil Diabetes & Endocrinology
Topeka, Kansas, 66606
Velocity Clinical Research, Panorama City
Van Nuys, California, 91405
MedVadis Research Corporation
Waltham, Massachusetts, 02451
IMA Clinical Research Warren
Warren Township, New Jersey, 07059
Chase Medical Research, LLC
Waterbury, Connecticut, 06708
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa, 50265
Argentina24 sites
Fundación Respirar
Buenos Aires, Buenos Aires, C1426ABP
Consultorio de Investigación Clínica EMO SRL
Buenos Aires, Buenos Aires F.D., 1405
Stat Research S.A.
Buenos Aires, Buenos Aires F.D., C1023AAB
Investigaciones Medicas Imoba Srl
Buenos Aires, Buenos Aires F.D., C1056ABH
Centro Médico Viamonte
Buenos Aires, Buenos Aires F.D., C1120AAC
Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
Buenos Aires, Buenos Aires F.D., C1425AGC
CEDIC
CABA, Buenos Aires, C1060ABN
Centro Medico Privado CEMAIC
Capital, Córdoba Province, X5008HHW
Centro de Investigaciones Metabólicas (CINME)
Ciudad Autónoma de Buenos Aires, Buenos Aires, 1056
IDIM - Instituto de Investigaciones Metabólicas
Ciudad de Buenos Aires, Buenos Aires, C1012AAR
Instituto Médico DAMIC
Córdoba, Córdoba Province, 5003DCE
Centro Medico Privado San Vicente Diabetes
Córdoba, Córdoba Province, 5006
MICA - Medicina e Investigación Cardiometabólica
Del Viso, Buenos Aires, 1669
CIPADI - Centro Integral de Prevencion y Atencion en Diabetes
Godoy Cruz, Mendoza Province, 5501
Centro de Investigaciones Clínicas Baigorria
Granadero Baigorria, Santa Fe Province, 2152
Instituto de Investigaciones Clínicas Mar del Plata
Mar del Plata, Buenos Aires, 7600
DIM Clínica Privada
Ramos Mejía, Buenos Aires, B1704ETD
INECO Neurociencias Oroño
Rosario, Santa Fe Province, 2000
Instituto de Investigaciones Clinicas Rosario
Rosario, Santa Fe Province, 2000
Centro de Investigaciones Médicas Tucuman
SAN M. de Tucuman, Tucumán Province, T4000AXL
Centro de Investigaciones Clinicas del Litoral
Santa Fe, Santa Fe Province, S3000FWO
Centro de Salud e Investigaciones Médicas
Santa Rosa, La Pampa Province, 6300
Sanatorio Norte
Santiago del Estero, Santiago del Estero Province, 4200
Sanatorio San Martin
Venado Tuerto, Santa Fe Province, 2600
Australia19 sites
Fusion Clinical Research
Adelaide, South Australia, 5000
Nightingale Research
Adelaide, South Australia, 5000
Emeritus Research
Botany, New South Wales, 2019
Box Hill Hospital
Box Hill, Victoria, 3128
Royal Brisbane and Women's Hospital
Brisbane, Queensland, 4029
Core Research Group
Brisbane, Queensland, 4064
Northern Beaches Clinical Research
Brookvale, New South Wales, 2100
Emeritus Research
Camberwell, Victoria, 3124
Camden Hospital
Camden, New South Wales, 2570
Canberra Hospital
Canberra, Australian Capital Territory, 2605
Barwon Health
Geelong, Victoria, 3220
Austin Health - Repatriation Hospital
Heidelberg West, Victoria, 3081
CDH Research Institute
Maroochydore, Queensland, 4558
Logan Hospital
Meadowbrook, Queensland, 4131
The AIM Centre / Hunter Diabetes Centre
Merewether, New South Wales, 2291
Southern Adelaide Diabetes & Endocrine Services
Mount Gambier, South Australia, 5290
One Clinical Research
Nedlands, Western Australia, 6009
Southern Adelaide Diabetes & Endocrine Services
Oaklands Park, South Australia, 5046
University of Sydney - Charles Perkins Centre
Sydney, New South Wales, 2006
Canada17 sites
Joanne F. Liutkus Medicine Professional Corporation
Cambridge, Ontario, N3H 4L5
Ecogene-21 - Cmas
Chicoutimi, Quebec, G7H 0S7
Ecogene-21
Chicoutimi, Quebec, G7H 7K9
LMC Clinical Research Inc. (Thornhill)
Concord, Ontario, L4K 4M2
Dr. Steven V. Zizzo Research Professional Corporation
Hamilton, Ontario, L8J 0B6
Milestone Research Inc.
London, Ontario, N5W 6A2
Clinique de médecine Urbaine du Quartier Latin
Montreal, Quebec, H2L 4E9
North York Diagnostic and Cardiac Centre
North York, Ontario, M6B 3H7
Centricity Research Oshawa
Oshawa, Ontario, L1J 2K9
Kawartha Cardiology Clinical Trials
Peterborough, Ontario, K9J 0B2
Syneos Health
Québec, Quebec, G1P0A2
CardioVasc HR Inc
Saint-Jean-sur-Richelieu, Quebec, J3A 1J2
Centre de Medecine Metabolique de Lanaudiere (CMML)
Terrebonne, Quebec, J6X 4P7
Manna Research Toronto
Toronto, Ontario, M9W 4L6
C.I.C. Mauricie inc.
Trois-Rivières, Quebec, G8T 7A1
BC Diabetes Office
Vancouver, British Columbia, V5Y 3W2
Discovery Clinical Services
Victoria, British Columbia, V8T 5G4
Mexico16 sites
Investigacion En Salud Y Metabolismo S.C / Nutricion Clinica / Unidad de Base de Datos
Chihuahua City, Chihuahua, 31110
Lahoja. Asociacion Para La Investigacion Y La Farmacovigilancia
Durango, Durango, 34000
Unidad de Investigación Clínica y Atención Médica HEPA
Guadalajara, Jalisco, 44670
EME RED Hospitalaria
Mérida, Yucatán, 97000
Medical Care and Research SA de CV
Mérida, Yucatán, 97070
RM Pharma Specialists
Mexico City, Mexico City, 03100
Centro Especializado En Diabetes, Obesidad Y Prevencion De Enfermedades Cardiovasculares
Mexico City, Mexico City, 11650
IMED Internal Medicine Clin Trials
Monterrey, Nuevo León, 64060
Clínica García Flores SC
Monterrey, Nuevo León, 64610
Eukarya PharmaSite
Monterrey, Nuevo León, 64718
Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
Monterrey, Nuevo León, 66460
Centro Multidisciplinario de Diabetes de Pachuca
Pachuca, Hidalgo, 42084
Centro de Atención e Investigación Cardiovascular del Potosí
San Luis Potosí City, San Luis Potosí, 78200
Centro de Investigacion Cardiovascular y Metabólica
Tijuana, Estado de Baja California, 22500
FAICIC S. de R.L. de C.V.
Veracruz, Veracruz, 91900
Centro de Investigacion Medica de Occidente, S.C.
Zapopan, Jalisco, 44260
Spain14 sites
Hospital Universitario de La Ribera
Alzira, Valenciana, Comunitat, 46600
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona [Barcelona], 08035
Hospital Universitario Reina Sofia
Córdoba, Andalusia, 14004
Complejo Hospitalario Universitario de Ferrol (CHUF)- Hospital Naval
Ferrol, A Coruña [La Coruña], 15405
Hospital Universitario Arnau de Vilanova de Lleida
Lleida, Lleida [Lérida], 25198
Hospital General Universitario Gregorio Marañon
Madrid, Madrid, 28009
Hospital Universitario Virgen de la Victoria
Málaga, Andalusia, 29010
Hospital Universitari Son Espases
Palma, Balears [Baleares], 07120
Hospital Virgen del Camino
Sanlúcar de Barrameda, Cádiz, 11540
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, 39008
Hospital Quiron Infanta Luisa
Seville, Andalusia, 41010
Hospital Universitario Virgen Del Rocio
Seville, Sevilla, 41013
Vithas Hospital Sevilla
Seville, Sevilla, 41950
Hospital Virgen de las Montañas
Villamartín, Cádiz, 11650
Hungary12 sites
DRC Gyógyszervizsgáló Központ
Balatonfüred, Veszprém megye, 8230
Óbudai Egészségügyi Centrum
Budapest, Budapest, 1036
ClinDiab Kft.
Budapest, Budapest, 1089
TRANTOR'99 Bt. Anyagcsere Centrum
Budapest, Budapest, 1213
Debreceni Egyetem Klinikai Központ
Debrecen, Debrecen, 4031
Óbudai Egészségügyi Centrum - Kaposvár Site
Kaposvár, Somogy County, 7400
Medifarma 98 Kft
Nyíregyháza, Nyíregyháza, 4400
Szent Lázár Megyei Kórház
Salgótarján, Nógrád megye, 3100
Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ
Szeged, Csongrád megye, 6725
Regia Med Kft
Székesfehérvár, Fejér, 8000
Zala Megyei Szent Rafael Kórház
Zalaegerszeg, Zala County, 8900
Óbudai Egészségügyi Centrum - Zalaegerszeg
Zalaegerszeg, Zalaegerszeg, 8900
Poland9 sites
KLIMED Marek Klimkiewicz
Bialystok, Podlaskie Voivodeship, 15-704
Ambulatorium Sp. z o.o.
Elblag, Warmian-Masurian Voivodeship, 82-300
Centrum Badan Klinicznych PI-House sp. z o.o.
Gdansk, Pomeranian Voivodeship, 80-546
Centrum Medyczne Pratia Katowice
Katowice, Silesian Voivodeship, 40-081
NZOZ Salvia CM
Katowice, Silesian Voivodeship, 40-772
Medyczne Centrum Diabetologiczno Endokrynologiczno Metaboliczne DIAB-ENDO-MET
Krakow, Lesser Poland Voivodeship, 31-261
Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo-Akcyjna
Lodz, Łódź Voivodeship, 90338
NBR Polska
Warsaw, Masovian Voivodeship, 00-710
Samodzielny Publiczny Szpital Kliniczny nr 1 SUM
Zabrze, Silesian Voivodeship, 41-800
Slovakia9 sites
Metabol KLINIK
Bratislava, Bratislava Region, 811 08
MediTask
Bratislava, 831 03
Diab - Int
Bytča, Žilina Region, 014 01
Human Care s.r.o.
Košice, Košice Region, 04001
Nemocnica s poliklinikou Lucenec
Lučenec, Banská Bystrica Region, 984 01
MediVet s.r.o.
Malacky, Bratislava Region, 901 01
Tatratrial s.r.o.
Rožňava, Košice Region, 04801
MEDI-DIA s.r.o.
Sabinov, Presov, 083 01
Areteus s.r.o.
Trebišov, Košice Region, 075 01
Puerto Rico3 sites
Ponce Medical School Foundation Inc.
Ponce, 00716
Clinical Research Management Group Inc
Ponce, 00717
Latin Clinical Trial Center
San Juan, 00909
About this study
Official title: A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
- Conditions
- Obesity, Cardiovascular Diseases
- Being tested
- Retatrutide, Placebo
- Medical subject headings
- Obesity, Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RetatrutideDrug
Also called LY3437943
Administered SC
PlaceboDrug
Administered SC
| Study group | Role | What they receive |
|---|---|---|
| Retatrutide Dose 1 | Experimental | Participants will receive retatrutide subcutaneously (SC). Receives: Drug: Retatrutide |
| Retatrutide Dose 2 | Experimental | Participants will receive retatrutide SC. Receives: Drug: Retatrutide |
| Placebo | Placebo comparator | Participants will receive placebo. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent Change from Baseline in Body Weight
Measured: Baseline, Week 80
Secondary outcomes (10)
Change from Baseline in Body Mass Index (BMI)
Measured: Baseline, Week 80
Change from Baseline in Waist Circumference
Measured: Baseline, Week 80
Percent Change from Baseline in Total Cholesterol
Measured: Baseline, Week 80
Percent Change from Baseline in Triglycerides
Measured: Baseline, Week 80
Change from Baseline in Systolic Blood Pressure (SBP)
Measured: Baseline, Week 80
Change from Baseline in Diastolic Blood Pressure (DBP)
Measured: Baseline, Week 80
Change from Baseline in Hemoglobin A1c (HbA1c)
Measured: Baseline, Week 80
Percent Change from Baseline in Fasting Insulin
Measured: Baseline, Week 80
Change from Baseline in Short Form version 2 (SF-36v2) Acute Form Physical Function Domain Score
Measured: Baseline, Week 80
Pharmacokinetics (PK): Steady State Area Under the Concentration Time Cure (AUC)
AUC is presented as a single average measure of AUC across the study duration.
Measured: Baseline to Week 80
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 May 2023
- Study start30 May 2023
- Primary completion16 Apr 2026
- Study completion14 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ObesityStudies of the same condition, open and under way.
- More trials run by Eli Lilly and CompanyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 1,946 participants (actual)
Sponsor and investigators
- Lead sponsor
- Eli Lilly and Company
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Study director, Eli Lilly and Company
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05882045
- Sponsor's protocol ID
- 18582
- Other IDs
- J1I-MC-GZBM, 2023-503659-88-00, 2023
- Acronym
- TRIUMPH-3
- Status last verified
- Jul 2026
- First submitted
- 22 May 2023
- Last updated
- 30 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Study at a glance
From the registry record, last updated by the sponsor on 30 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease
- ClinicalTrials.gov ID
- NCT05882045
- Acronym / sponsor ID
- TRIUMPH-3 / 18582
- Conditions
- Obesity, Cardiovascular Diseases
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,946 participants (actual)
- Lead sponsor
- Eli Lilly and CompanyIndustry (pharma, biotech, devices)
- Study start
- 30 May 2023 (actual)
- Primary completion
- 16 Apr 2026 (actual)
- Study completion
- 14 May 2026 (actual)
- First posted
- 31 May 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Retatrutide Dose 1 | Experimental | Drug: RetatrutideParticipants will receive retatrutide subcutaneously (SC). |
| Retatrutide Dose 2 | Experimental | Drug: RetatrutideParticipants will receive retatrutide SC. |
| Placebo | Placebo comparator | Drug: PlaceboParticipants will receive placebo. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Have a body mass index (BMI) ≥35.0 kilogram/square meter (kg/m²).
- Have established cardiovascular (CV) disease with at least 1 of the following:
- Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight.
Key exclusion criteria (7 listed)
- Have had acute myocardial infarction, stroke, coronary revascularization, hospitalization for unstable angina, or hospitalization due to congestive heart failure within 90 days prior to screening.
- Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening.
- Have a prior or planned surgical treatment of obesity.
- Have a change in body weight greater than 5 kg (11 pounds) within 90 days prior to screening.
- Have Type 1 diabetes.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RetatrutideAlso: LY3437943Administered SC | Drug | Retatrutide Dose 1, Retatrutide Dose 2 |
| PlaceboAdministered SC | Drug | Placebo |
Primary outcome
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 80
10 secondary outcomes
Change from Baseline in Body Mass Index (BMI)
Time frame: Baseline, Week 80
Change from Baseline in Waist Circumference
Time frame: Baseline, Week 80
Percent Change from Baseline in Total Cholesterol
Time frame: Baseline, Week 80
Percent Change from Baseline in Triglycerides
Time frame: Baseline, Week 80
Change from Baseline in Systolic Blood Pressure (SBP)
Time frame: Baseline, Week 80
Change from Baseline in Diastolic Blood Pressure (DBP)
Time frame: Baseline, Week 80
Change from Baseline in Hemoglobin A1c (HbA1c)
Time frame: Baseline, Week 80
Percent Change from Baseline in Fasting Insulin
Time frame: Baseline, Week 80
Change from Baseline in Short Form version 2 (SF-36v2) Acute Form Physical Function Domain Score
Time frame: Baseline, Week 80
Pharmacokinetics (PK): Steady State Area Under the Concentration Time Cure (AUC)
Time frame: Baseline to Week 80
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jul 2026.
- A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)Link provided by the sponsor.
- Individual participant dataSharing planned: Yes. Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) study director
Eli Lilly and Company
169 sites in 10 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Retatrutide in people with Obesity and Cardiovascular Diseases, run by Eli Lilly and Company at 169 sites in 10 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 169 sites in United States, Argentina, Australia, Canada, Mexico and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percent Change from Baseline in Body Weight (time frame: Baseline, Week 80). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2026.